RxDoctor Payments Data

Anita Akewusola

Family · Pasadena, MDNPI 1407633274

Payments from drug & device makers

$829in general payments, 2019–2025

Across 28 payments — averaging $29.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$216
  • Alkermes, Inc.$181
  • Gilead$163
  • AbbVie$61
  • Vanda Pharmaceuticals Inc.$37
  • Neurocrine Biosciences, Inc.$34
  • plus $136 from 6 others

What the payments were for

  • Food & beverage$82099%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$829 in reported general payments places this provider in the 65th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$62,703
Medicare patients
183
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$12,503
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$6,758
FarxigaDapagliflozin Propanediol14$5,392
OxycontinOxycodone Hcl12$3,394
Oxycodone Hcl80$1,587
Levetiracetam22$1,189
Doxycycline Hyclate16$860
Pregabalin13$624
Divalproex Sodium26$582
Insulin Glargine-Yfgn18$577
Mirtazapine25$555
Clonazepam25$489
Bupropion Hcl14$487
Trazodone Hcl24$465
Albuterol Sulfate HfaAlbuterol Sulfate11$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$17$42915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,843 family providers in Maryland.

Other family in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →